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ABSTRACT 
Background and aims: Subjects with chronic obstructive pulmonary 
disease (COPD) have comorbidities and an increased mortality rate. However, 
long-term follow-up data on COPD and mortality appear incomplete. This 
study aimed to evaluate whether airway obstruction at baseline predicts acute 
myocardial infarction (MI) and coronary and all-cause mortality, and whether 
past pulmonary tuberculosis (TB) or a low vitamin D status confounds or 
modifies the association between obstruction and mortality during a 30-year 
follow-up.  
Methods: A national health examination survey, the Mini-Finland Health 
Survey performed between 1978 and 1980, collected data among 8000 
subjects in a sample representing the Finnish adult population. Studies I to IV 
consisted of 5576 to 6701 subjects who underwent spirometry at baseline and 
had all of the necessary information collected for each study. Baseline data 
were linked to follow-up data from various databases. Obstruction was defined 
either using a fixed ratio of the forced expiratory volume in 1 second per forced 
vital capacity (FEV1/FVC) < 0.7 or FEV1/FVC below the lower limit of normal 
(LLN) categorization, and staged for severity based on the Global Initiative for 
Chronic Obstructive Lung Disease classification (GOLD stages 1–4). 
The cross-sectional baseline associations between obstruction and 
different characteristics were analyzed through logistic regression analysis, 
with the results expressed as adjusted odds ratios (ORs) with 95% confidence 
intervals (95% CIs). In the cohort design, the Cox’s proportional hazard model 
was used and the adjusted hazard ratios (HRs) with 95% CIs were estimated. 
Analyses were performed using the SAS System for Windows (SAS Institute, 
Inc., Cary, NC, version 9.1, 9.2, or 9.3) or IBM’s SPSS Statistics (version 23 or 
24). 
Results: During follow-up, the GOLD stage had a strong significant 
association with all-cause mortality. Respectively, HRs (95% CIs) in GOLD 
stages 1–4 were 1.27 (1.06–1.51), 1.40 (1.21–1.63), 1.55 (1.22–1.97), and 2.85 
(1.65–4.94) compared to those with FEV1/FVC ≥ 0.7. The risk for 
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cardiovascular mortality was consistently increased in GOLD stages 1–4 in 
age, sex, and smoking and in multivariate adjusted models, although no 
association emerged after excluding those with cardiovascular disease at 
baseline. GOLD stages 2–4 predicted all-cause mortality strongest in subjects 
aged 30 to 49 at baseline (study I).   
In addition, obstruction predicted coronary mortality, but not MI among 
those without cardiovascular disease at baseline. Respectively, HRs (95% CIs) 
for coronary mortality and MI in subjects with obstruction were 1.40 (1.04–
1.88) and 0.84 (0.54–1.31) when compared to those without. In the subgroup 
analysis, obstruction predicted MI and coronary death among women aged 30 
to 49 at baseline (study II).  
In addition, past pulmonary TB, determined either as a TB disease history 
or a scar indicated via chest x-ray, had an association with obstruction in a 
cross-sectional study. During follow-up, past TB and obstruction predicted all-
cause mortality through an additive pattern (study III). 
Finally, obstruction and vitamin D status predicted all-cause mortality 
independently of each other during follow-up. The association between a low 
vitamin D status and mortality was particularly pronounced among subjects 
with obstruction. Respectively, HRs (95% CIs) for subjects without and with 
obstruction in the highest tertiles of vitamin D status were 0.89 (0.81–0.98) 
and 0.57 (0.40–0.80) when compared to those with the lowest tertile (study 
IV).   
Conclusions: Airway obstruction predicts all-cause mortality by 
decreasing lung function, and obstruction appears to increase mortality risk 
particularly in younger populations. Obstruction strongly determines 
coronary mortality, but not the risk of MI. Moreover, obstruction and past TB 
have an additive effect on all-cause mortality. Finally, a low vitamin D status 
may be particularly detrimental among subjects with obstruction. 
 
Keywords: airway obstruction, mortality, epidemiological study, 
coronary mortality, myocardial infarction, pulmonary tuberculosis, serum 25-
hydroxyvitamin D 
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YHTEENVETO 
Esitiedot ja tutkimuksen tarkoitus: Keuhkoahtaumatautiin liittyy muita 
pitkäaikaisia sairauksia ja ennenaikaisen kuoleman riski. 
Seurantatutkimuksia aiheista on melko niukasti ja tieto on vajavaista. 
Väitöskirjatutkimuksen tarkoituksena oli analysoida lähtötilanteen 
poikkileikkausasetelmassa mitatun keuhkoputkien ahtauman (obstruktion) 
yhteyttä eri tekijöihin ja arvioida kohorttiasetelmassa obstruktion ja näiden 
tekijöiden vaikutuksia kokonais- ja sepelvaltimotautikuolleisuuteen sekä 
akuutin sepelvaltimotautikohtauksen riskiin yli 30 vuoden seurannan aikana. 
Metodit: Tutkimusaineistona oli Suomessa vuosina 1978–1980 
toteutetun Mini-Suomi -väestötutkimuksen aineisto, johon yhdisteltiin 
rekisteriseurantatietoja. Tutkimukseen kutsuttu 8000 henkilön otos edusti 
suomalaista aikuisväestöä. Tämän väitöskirjatutkimuksen osatöiden 
analyyseissa olivat mukana ne 5576–6701 henkilöä, joilta löytyivät kussakin 
osatyössä tarvitut tiedot (sisältäen spirometrian). Obstruktio määriteltiin joko 
kiinteällä spirometrian raja-arvolla FEV1/FVC <0.7 tai iän, sukupuolen ja 
pituuden mukaan määritetyllä lower limit of normal -raja-arvolla (LLN) ja 
luokiteltiin vaikeusasteisiin 1–4 GOLD-luokituksen mukaisesti.  
Obstruktion ja eri muuttujien poikkileikkausyhteyksiä analysoitiin 
logistisilla malleilla, jolloin tulokset ilmaistiin vakioituina vetosuhteina (odds 
ratio, OR) 95 %:n luottamusväleineen. Seurantatietoja analysoitiin Coxin 
mallilla (Cox´s proportional hazards models), ja tulokset ilmaistiin 
riskitiheyssuhteina (hazard ratio, HR) 95 %:n luottamusväleineen. 
Tilastollisissa analyyseissa käytettiin joko SAS- (SAS System for Windows, 
versio 9.1, 9.2 tai 9.3, SAS Institute, Inc., Cary, NC) tai SPSS-järjestelmää (IBM 
SPSS statistics, versio 23 tai 24). 
Tulokset: Mitä vaikeampi obstruktio perustutkimuksessa todettiin, sitä 
suurempaa kokonaiskuolleisuus oli seurannassa. Vastaavat HR-luvut (95 % 
luottamusväleillä) olivat GOLD-luokissa 1–4 1.27 (1.06–1.51), 1.40 (1.21–
1.63), 1.55 (1.22–1.97) ja 2.85 (1.65–4.94), kun vertailuryhmänä olivat ne, 
joilla FEV1/FVC oli ≥0.7. Obstruktion ja kokonaiskuolleisuuden välillä oli 
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voimakkain yhteys nuorimmalla ikäryhmällä (30–49-vuotiailla). Sydän- ja 
verisuonisairauskuolleisuus oli lisääntynyt yhtä paljon kaikissa GOLD-
luokissa. Yhteyttä ei enää todettu, kun mallista poistettiin ne henkilöt, joilla 
oli perustutkimuksessa todettu jokin muu sydän- tai verisuonisairaus kuin 
komplisoitumaton verenpainetauti (osatyö I).  
Obstruktio ennusti seurantatutkimuksessa sepelvaltimotautikuolleisuutta, 
mutta ei akuuttia sydäninfarktia; vastaavat HR-luvut (95 % luottamusväleillä) 
sepelvaltimotautikuolleisuudelle ja akuutille sydäninfarktille olivat 
obstruktiivisilla 1.40 (1.04–1.88) ja 0.84 (0.54–1.31) verrattaessa niihin, joilla 
ei ollut obstruktiota. Osajoukottaisessa analyysissa obstruktio ennusti 30–49-
vuotiailla naisilla akuuttia sydäninfarktia. Osatyön II analyyseista oli suljettu 
pois ne henkilöt, joilla perustutkimuksessa oli todettu jokin muu sydän- tai 
verisuonisairaus kuin komplisoitumaton verenpainetauti (osatyö II).    
Aikaisempi keuhkotuberkuloosi määriteltiin joko hoidettuna tautina tai 
keuhkojen röntgenkuvaan jääneenä tyypillisenä arpena. Aikaisemmalla 
keuhkotuberkuloosilla ja obstruktiolla oli kokonaiskuolleisuutta lisäävä 
additiivinen yhteisvaikutus. Vastaavat HR-luvut (95 % luottamusväleillä) 
olivat: niille joilla ei ollut aikaisempaa keuhkotuberkuloosia tai obstruktiota 1 
(vertailuryhmä), niille joilla oli aikaisempi keuhkotuberkuloosi mutta ei 
obstruktiota 1.1 (1.0–1.2), niille joilla oli obstruktio mutta ei aikaisempaa 
keuhkotuberkuloosia 1.6 (1.3–2.0) ja niille joilla oli molemmat 1.8 (1.5–2.2) 
(osatyö III).  
Alentunut D-vitamiinitaso ja obstruktio ennustivat toisistaan riippumatta 
kokonaiskuolleisuutta. Lisäksi todettiin tilastollisesti merkitsevä 
yhdysvaikutus (p = 0,007): matala D-vitamiinitaso oli voimakkaammin 
yhteydessä obstruktiivisten kuin muiden henkilöiden kuolleisuuteen. 
Vastaavat HR-luvut (95 % luottamusväleillä) olivat niillä, joilla ei ollut ja oli 
obstruktio korkeimmassa D-vitamiinitertiilissä 0.89 (0.81–0.98) ja 0.57 
(0.40–0.80) verrattuna matalimpaan tertiiliin (osatyö IV).  
Yhteenveto: Kokonaiskuolleisuus lisääntyy, kun obstruktio vaikeutuu. 
Obstruktio saattaa olla erityisen haitallista nuoremmissa ikäluokissa. 
Obstruktio ennustaa sepelvaltimotautikuolleisuutta, mutta ei akuuttia 
sydäninfarktia. Obstruktiolla ja aikaisemmalla keuhkotuberkuloosilla on 
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kuolleisuutta lisäävä additiivinen yhteisvaikutus. Matala D-vitamiinitaso voi 
lisätä enemmän obstruktiivisten kuin muiden henkilöiden ennenaikaista 
kuolleisuutta. 
 
 
Avainsanat: obstruktio ilmateissä, epidemiologia, kuolleisuus, 
sepelvaltimotautikuolleisuus, sydäninfarkti, keuhkotuberkuloosi, seerumin 
25-hydroksivitamiini-D 
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1 INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a slowly progressive disease 
causing non-reversible airway obstruction and leading to major morbidity and 
mortality worldwide. It’s suspected that COPD will be the third leading cause 
of death globally by 2020; in Finland, about 1000 individuals die from COPD 
yearly. The prevalence of COPD stood at 10.1% in an international study, and 
3.6% in one Finnish study; another study placed prevalence in Finland at 4.3% 
in men and 3.1% in women. COPD is primarily caused by smoking, and 
smoking cessation represents the most effective way to slow disease 
progression and decrease mortality [1-7]. 
Morbidity and mortality increase as COPD progresses and lung function 
decreases. Multiple factors, such as an increasing age, male sex, and a low body 
mass index (BMI), predict mortality in subjects with COPD. Additionally, 
many comorbidities–for instance, cardiovascular diseases, osteoporosis, 
cancer, and depression– have associations with COPD, decrease the quality of 
life, and increase mortality [1,5,8-21]. As COPD progresses, the number and 
severity of comorbidities often increase as well. The link between COPD and 
comorbidities continues have association with the poorly understood systemic 
inflammatory pathway [1,8,12-14,22,23].  
Cardiovascular diseases are among the most important comorbidities in 
COPD, where smoking is one of the main risk factors in cardiovascular 
diseases. Cardiovascular diseases are a common cause of death in subjects 
with COPD. Worldwide one in three deaths is caused by cardiovascular 
diseases–over 40% of cardiovascular deaths being coronary deaths 
[1,5,9,11,15,24].  
In addition to comorbidities, subjects with COPD suffer other diseases and 
conditions which have associations with common risk factors for COPD, 
particularly smoking. These other diseases include, for instance, chronic 
bronchitis, idiopathic pulmonary fibrosis, asthma, past pulmonary TB, and a 
low vitamin D status [1,25-30]. Since unique data were available about past TB 
and vitamin D status, this thesis focused on the associations between these 
factors and obstruction as well as their joint effects on mortality. 
Annually, about 9 million active tuberculosis infections occur globally; 
tuberculosis represents a major health problem causing unnecessary deaths 
when untreated. While tuberculosis is currently rare in Finland, prevalence 
was higher when the Mini-Finland Health Survey data were collected (50–80 
cases per 100 000 population), comparable to rates found in developing 
countries today [31-33].  
The current prevalence of low vitamin D status reaches up to 30% in 
Europe and 0.6% in Finland with the current vitamin D fortification policy; 
during the Mini-Finland Health Survey, vitamin D deficiency among Finns 
appeared higher [28,34,35]. A low vitamin D status, tuberculosis, and COPD 
Introduction 
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have all associations with similar factors, such as ageing, smoking, a low 
socioeconomic status, and chronic diseases [1,2,22,28,32,33,36-47].  
The material in this doctoral study stems from the Mini-Finland Health 
Survey, the first Finnish population-based health examination survey with 
7217 participants (90% of those invited participated) representing the adult 
Finnish population. Data were collected through interviews, clinical 
measurements, and examinations during the baseline study carried out from 
1978 through 1980, and subsequently followed-up using record linkage to 
various registers, such as the causes of death from Statistics Finland [48,49]. 
For this doctoral study, data were analyzed for 5576 to 6701 study subjects 
with all the necessary records for each study, including spirometry. Analysis 
focused on the cross-sectional baseline associations between obstruction and 
various factors, controlling for those associations, and evaluating whether 
obstruction at baseline predicted various endpoints (myocardial infarction 
(MI) and coronary, cardiovascular, and all-cause mortality) during the three-
decade follow-up after the baseline survey [48,50,51].  
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2 REVIEW OF THE LITERATURE 
Resources for the literature review were obtained through a PubMed search 
concentrating on publications from the last 10 years and which appeared in 
good-quality journals. A massive amount of scientific research on COPD, 
comorbidities, and mortality resulted; thus, this review focuses, on the one 
hand, on the highest-quality studies, and, on the other hand, studies which 
best correspond to the national health examination survey data we analyzed. 
However, almost all studies on the associations between COPD and 
cardiovascular mortality relying on a comparable study design to the Mini-
Finland Health Survey were performed 10 to 20 years ago, and were, therefore, 
included. In addition, limited data exist on some specifics, such as the effect of 
a low vitamin D status on mortality in subjects with COPD, and, therefore, all 
available resources related to such topics were used.  
2.1 WHAT IS CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE (COPD)? 
The first Finnish doctoral study on respiratory symptoms, chronic bronchitis, 
and pulmonary emphysema was published in 1965 in material where 82.3% of 
men and 13.9% women smoked, concluding that a chronic cough had an 
association with smoking with a prevalence of 25.3% in men and 5.7% in 
women. Respectively, the prevalence rates for chronic bronchitis and 
emphysema were 28.2% and 10.0% in men and 5.8 and 2.3% in women, and, 
a lower FEV1 had an association with smoking in men [52]. 
According to current data, COPD is primarily caused by smoking. However, 
in developing countries in particular never-smokers have COPD which 
appears to result from poverty related to in utero, early childhood exposures 
and continuing exposure to polluted air, smoke, dust, and fumes, as well as 
past TB [1,5,53]. 
COPD is defined as a chronic, progressive airway obstruction and chronic 
inflammation, and worldwide represents the most common chronic 
respiratory disease causing major unnecessary morbidity and mortality. Four 
characteristics contribute to COPD with varying roles in different patients: 
chronic bronchitis, airway obstruction, emphysema, and comorbidities. 
Chronic bronchitis is defined as a productive cough continuing for at least 
three months period and repeating at least two years after another; airway 
obstruction is defined as a decreased expirium caused by obstruction and 
emphysema; and emphysema is a non-reversible dilatation in dilated terminal 
airways and destroyed alveolar walls. Comorbidities include extra-pulmonary 
diseases which have association with COPD, such as cardiovascular diseases, 
metabolic syndrome, osteoporosis, and depression [1,7,36]. 
Review of the literature 
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2.2 DEFINITIONS FOR OBSTRUCTION  
No single definition for obstruction exists in international scientific use. This 
dissertation study was performed between 2010 and 2018, using the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) and the lower limit of 
normal (LLN) definitions for obstruction [1,54-58].  
GOLD is a committee of international COPD experts who provide annual 
updated recommendations for clinical use regarding the assessment, 
diagnosis, and treatment of COPD. During this doctoral study, GOLD specified 
COPD using three different definitions. Between 2001 and 2011, obstruction 
was defined using a fixed cut-off limit (FEV1/FVC < 0.7) with the degree of 
COPD classified further based on GOLD stages 1–4 (Figure 1). Between 2011 
and 2016, COPD was classified in ABCD groups which included, in addition to 
GOLD stages 1–4, respiratory symptoms and the number of COPD annual 
exacerbations. In these, COPD treatment recommendations were outlined 
based on the GOLD staging or ABCD classification. From 2017, GOLD 
classified COPD separately according to the degree of obstruction in GOLD 
stages 1–4 (FEV1/FVC < 0.7) and in ABCD groups according to the respiratory 
symptoms and the risk of annual COPD exacerbation. Treatment is currently 
recommended based on ABCD classification, while the diagnosis, prognosis, 
and other therapeutic approaches are based on GOLD stages 1–4 [1,54,55].  
The fixed cut-off limit for obstruction (FEV1/FVC < 0.7) might 
overestimate COPD in the elderly and underestimate it in subjects under 45 
years [1,54,55,59,60]. Therefore, use of the LLN definition, which categorizes 
the limit of obstruction individually for each subject according to their age, 
sex, and height, is recommended [56,58,61].  
 
 
Figure 1 GOLD stages according to GOLD in those with FEV1/FVC <0.7 [1]. 
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2.3 REFERENCE VALUES FOR OBSTRUCTION 
No single reference value for obstruction exists in international scientific use. 
This study used the Swiss study on air pollution and lung disease in adults 
(SAPALDIA) and the Global Lung Function Initiative (GLI) reference values 
for obstruction [56,58,62]. The SAPALDIA values, published in 1996, were 
determined for Swiss adults aged 18 to 60 and can be extrapolated up to age 
75  [56,62]. The GLI values, published in 2012, were determined from multi-
ethnic spirometry records from 97 759 healthy non-smokers aged 3 to 95 
based on the age, sex, and height of subjects. Furthermore, the GLI values were 
determined separately for four ethnic groups, while genetic variations in the 
spirometry results were found in the populations (body composition and the 
size of the thoracic cavity). Caucasians were drawn from a wide variety of 
geographical regions, although no Finns were included. The classification for 
the degree of obstruction according to GLI was published in 2014. The GLI 
reference values are currently recommended for international use [58,63]. 
In Finnish clinical use, the 1982 reference values published by Viljanen et 
al. were determined from a selected occupational cohort of 553 subjects aged 
18 to 65. Consequently, these values are not appropriate for the elderly. 
Additionally, Finns’ average height has increased by almost 5 cm from the 
1980s. The current lung volume in the Finnish population appears larger than 
predicted values according to GLI, thus strengthening the need for revised 
Finnish national reference values, presented by Kainu et al. in 2016. These 
values were determined from a sample of 1000 native, non-smoking Finns 
aged 18 to 83 using LLN and categorizing the degree of obstruction according 
to GLI [57,58,61,63,64].  
2.4 OBSTRUCTION AND COMORBIDITIES  
Comorbidities such as cardiovascular diseases, osteoporosis, and depression 
have association with COPD and diminish the quality of life. This has also been 
defined as multi-morbidity. Many of these comorbidities share risk factors 
with COPD, including an increasing age, smoking, and being male. The 
number and severity of comorbidities typically increases as COPD progresses, 
and comorbidities increase mortality among subjects with COPD. Moreover, 
many subjects die from diseases other than COPD, whereby the other primary 
causes of death are cardiovascular diseases, cancers, and other respiratory 
diseases [1,8,9,12,13,17,19,21,54,65].  
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2.5 OBSTRUCTION AND ALL-CAUSE 
MORTALITY 
Smoking was found to have association with lung cancer as early as the 1950s, 
and COPD and a decreased lung function (decreased FEV1) with all-cause 
mortality in the late 1980s and 1990s, an association strengthened in 
subsequent studies. All-cause mortality increases as COPD progresses and 
lung function decreases, particularly in current smokers but also in never-
smokers. Both of the most commonly used definitions for obstruction (GOLD 
staging and LLN) predict mortality based on decreasing lung function [1,15-
17,19,66-71]. The most significant factor explaining the association between 
reduced FEV1 and all-cause mortality appears to be inflammatory markers, 
followed by coronary heart disease, stroke, and diabetes, and further by 
alcohol consumption, diet, physical activity, and BMI in a model adjusted for 
age, sex, and smoking [72].  
2.6 OBSTRUCTION AND CARDIOVASCULAR 
COMORBIDITIES AND MORTALITY 
Previous studies found associations between COPD and cardiovascular 
diseases in general and specifically with hypertension, coronary heart disease, 
heart failure, arrhythmias, peripheral vascular disease, and hypertension. 
However, previous studies on COPD and stroke showed both an association 
and no association [1,8,9,11-13,19,73-75].  
Both, COPD and cardiovascular diseases predict all-cause mortality 
[1,13,18,24,65]. The association between COPD and decreased FEV1 and 
cardiovascular mortality was demonstrated in large population-based studies 
published over 10 years ago. COPD predicts cardiovascular mortality in 
models adjusted for general cardiovascular disease risk factors and in studies 
with a long-term follow-up. In general, mortality increases as lung function 
decreases [11,13,18,65,76].  
2.7 OBSTRUCTION AND ACUTE MYOCARDIAL 
INFARCTION (MI) AND CORONARY 
MORTALITY 
Studies about the association between COPD and coronary mortality as well 
as MI are presented in Tables 1 and 2. According to these studies, COPD 
appears to have an association with coronary mortality in multivariate 
adjusted analyses, in studies among subjects without a baseline cardiovascular 
disease, in long-term follow-up studies, and in both sexes [11,15,18,22,77-80].  
COPD and MI had an association in two previous studies among subjects 
without a baseline cardiovascular disease. Yet, cross-sectional and other 
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follow-up studies found both an association and no association between COPD 
and MI   [11,22,74,78,81-87]. 
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2.8 TUBERCULOSIS  
Tuberculosis is a bacterial disease caused by Mycobacterium tuberculosis. 
Worldwide one in three individuals has latent tuberculosis, defined as an 
immunological sensitization to mycobacterial proteins, although only 10% of 
those with latent infection ever develop active tuberculosis. Yet, 9 million 
active tuberculosis infections occur yearly. Globally tuberculosis is the ninth 
leading cause of death and the leading lethal infectious disease concentrated 
in middle- and low-income countries. It has associations with poverty, 
smoking, and undernutrition. Many noncommunicable diseases such as 
diabetes as well as environmental exposures predispose individuals to active 
tuberculosis. Co-infection with HIV and drug-resistance tuberculosis strain 
increase mortality. Yet, most deaths from TB remain preventable through 
early diagnosis and proper treatment [32,33,36,88]. 
2.8.1 OBSTRUCTION AND PULMONARY TUBERCULOSIS (TB) 
COPD increases the risk for developing active TB, while treated active TB 
represents a risk for COPD. Yet, some previous case–control studies showed 
no association. The strength of the association between past TB and 
obstruction correlates with the incidence rates of TB and appears stronger in 
adults under 40. The loss of lung function continues years after TB treatment 
depending on the severity of disease [29,36-38,41-43,53,89]. A disease history 
of TB appears to be a significant risk factor for COPD in non-smokers in 
developing countries, and the disease differs from COPD caused by smoking 
[90,91].  
An abnormal chest x-ray with cavitation, bronchiechtasis, fibrosis, and 
pleural thickening is common after treated active TB [92]. A TB indicative scar 
on a chest x-ray and latent TB also have an association with COPD and 
obstruction [36,39-41,93,94]. A TB-indicative scar predicts a decreasing FEV1 
in never-smokers as well [39,41], although a TB disease history has a stronger 
association with obstruction compared to a TB-indicative scar [95].  
COPD and past TB, defined as a TB disease history or a TB-indicative scar 
on a chest x-ray, have an association with multiple similar factors, such as 
smoking, poverty, undernutrition, ageing, and comorbidities. Researchers 
suspect the association between TB and COPD is bidirectional, for instance, 
with lung remodeling and an immunological mechanism, occurring 
independently of common risk factors [1,32,33,36-38,93,96]. 
2.8.2 OBSTRUCTION, PAST TB, AND ALL-CAUSE MORTALITY 
COPD and active TB cause mortality [1,37,97,98]. Additionally, a TB-
indicative scar on a chest x-ray and a TB disease history predict all-cause 
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mortality in long-term follow-up as well as TB disease history mortality in 
COPD [37,98,99]. COPD increases all-cause mortality during the first year 
following an active TB diagnosis, although subjects with COPD had more 
comorbidities than those without COPD [43].  
2.9 LOW VITAMIN D STATUS  
2.9.1 OBSTRUCTION AND LOW VITAMIN D STATUS  
A low vitamin D status results from insufficient dietary intake and inadequate 
exposure to sunlight generally measured as the serum 25-hydroxyvitamin-D 
(25(OH)D) concentration–that is, a value <30 nmol/L indicates deficiency 
and <50 nmol/L insufficiency. The prevalence of vitamin D deficiency was 
0.6% in Finland according to the Health 2011 Survey following the current 
vitamin D fortification policy. In comparison, prevalence was 13% in the 
Health 2000 Survey before dietary fortification began. Respectively, the mean 
25(OH)D concentrations were 65.4 nmol/L in the Health 2011 Survey, 47.6 
nmol/L in the Health 2000 Survey, and 43.4 nmol/L in men and 41.5 nmol/L 
in women, respectively, in the Mini-Finland Health Survey [28,34,35,100].  
Vitamin D metabolism is complex and the link between vitamin D 
metabolism and COPD remains unconfirmed. It’s suspected that a low vitamin 
D status plays a role in immune defense, airway remodelling, and 
inflammatory reactions in COPD [28,45,101-103]. A review article 
summarized the results of previous studies about the association between lung 
functions and vitamin D status, finding inconsistent conclusions across 
studies [28]. For instance, in the National Health Examination Survey 
(NHANES), researchers found a difference in the FEV1 and FVC levels between 
the highest and lowest vitamin D status quintiles, although that difference 
diminished after adjusting for confounders [103]. In another study, a low 
vitamin D status had an association with COPD, correlating with the severity 
of COPD [102].  
A low vitamin D status and COPD have associations with multiple similar 
factors, such as ageing, smoking, inactivity, staying indoors, a low 
socioeconomic status, and chronic diseases, which might confound the 
association [1,2,22,28,46,47]. Epidemiological data about the associations 
between COPD and a low vitamin D status remain limited [101]. 
2.9.2 OBSTRUCTION, LOW VITAMIN D STATUS, AND ALL-CAUSE 
MORTALITY 
A low vitamin D status and COPD predicted all-cause mortality in follow-up 
studies, revealing an inverse association between mortality and lung function 
as well as vitamin D status [1,2,15,22,46,47,104-106]. However, only three 
previous studies evaluated the effect of a low vitamin D status on all-cause 
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mortality in subjects with COPD with a long-term follow-up, and in those no 
correlation emerged [105,107,108]. 
2.10 HEALTH EXAMINATION SURVEYS 
EXAMINING OBSTRUCTION 
2.10.1 FINNISH SURVEYS 
2.10.1.1 Mini-Finland Health Examination Survey 
This doctoral study was based on the Mini-Finland Health Examination 
Survey, the first national health examination survey. It was carried out 
between 1978 and 1980 by the Social Insurance Institution. The survey aimed 
to produce extensive data in health, disease prevalence and incidence, and any 
factors having association with them. The study population represented the 
adult Finnish population aged 30 and older. As a result, a massive amount of 
data was collected from each study participant about, for instance, their 
disease history, disabilities, symptoms, socioeconomic status, occupation, and 
various behavioral factors [48,51,109]. 
The baseline examination was performed by a moving unit, the Mobile 
Clinic, in 40 areas, where local nurses first conducted home interviews. 
Personnel from the Social Insurance Institution’s Mobile Clinic gathered all 
other data, such as various measurements, tests, serological determinations, 
spirometry, and a chest x-ray. Subjects with abnormal results were invited to 
participate in the second stage of the baseline examination, including a 
standard physical examination performed by a physician. The results from the 
survey and subsequent follow-up through record linkage to national registers 
have been reported in dozens of doctoral studies and more than 300 original 
articles [51,109].  
2.10.1.2 Health 2000 Survey, Health 2011 Survey, and other 
surveys 
The Health 2000 Survey was the next Finnish national health examination 
survey performed between 2000 and 2001 using similar objects and 
measurements to those in the Mini-Finland Health Survey. A sample of 10 000 
subjects represented adult Finns aged 18 years and older. The Health 2011 
Survey was a follow-up study to the Health 2000 Survey´s sample, aged at that 
time 29 and older, with a new random sample of persons aged 18 to 28. The 
Health 2000 and Health 2011 surveys used comparable methods including 
spirometry [110,111]. 
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Every fifth year between 1972 and 2012, the national FINRISK Study was 
carried out. FINRISK was a population study which collected data about risk 
factors for chronic, noncommunicable diseases. The FINRISK Study and the 
Health 2000 Survey were combined in 2017 to form a new population study 
(FinHealth Survey), which is planned for every fifth year. No spirometry was 
included in the FinHealth 2017 study, although it is hopefully planned for the 
FinHealth 2022 study [112,113].  
2.10.2 SCANDINAVIAN HEALTH EXAMINATION SURVEYS  
2.10.2.1 Obstructive Lung Disease in Northern Sweden (OLIN) 
Study, Sweden 
OLIN Study is a large longitudinal population-based study. This study consists 
of data from a  stratified or random sample of over 50 000 Swedish subjects 
ranging from children to the elderly living across Norbotten county in Sweden 
collected in several cohorts beginning in 1985. Health data were gathered 
through structured interview and examinations including spirometry [115-
117]. 
2.10.2.2 Copenhagen City Heart Study (CCHS), Denmark 
The longitudinal population-based CCHS study conducted from 1975, was 
primarily designed to study cardiovascular diseases, but later added on other 
issues such as pulmonary diseases. The first phase of CCHS included a random 
sample of 20 000 adult subjects from the Copenhagen city population. Data 
were collected through questionnaires and examinations including 
spirometry. In follow-up studies, the same population was invited to take part, 
while adding new samples from younger age groups [15,118].   
2.10.2.3 The Nord-Trondelag Health (HUNT) Study, Norway 
HUNT Study is a large population-based Norwegian cohort study consisting 
of 125 000 participants. Every subject aged 20 or older from Nord-Trondelag 
County in Norway was invited to take part in the HUNT1, HUNT2, and HUNT3 
studies performed between 1984 and 1986, 1995 and 1997, and 2006 and 
2008. Spirometry was performed for a subgroup of the HUNT2 and HUNT3 
samples [119].  
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2.10.3 OTHER COUNTRIES AND INTERNATIONAL SURVEYS 
2.10.3.1 National Health Examination Survey (NHANES) in 
USA 
NHANES has been performed in the USA since the early 1960s through 
various schemes. From 1999, about 5000 subjects have been examined 
annually in a nationally representative population sample across the USA. 
NHANES collects comprehensive health data through questionnaires, 
interviews, and examinations, including spirometries for part of the sample 
[115,120,121]. 
2.10.3.1 Framingham Heart Study 
The Framingham Heart Study is a population-based cohort study originally 
among 5209 participants aged 28 to 62 established in 1948 in Framingham, 
MA, USA. After the original cohort, data were collected from new cohorts 
[122,123]. 
2.10.3.2 The Burden of Obstructive Lung Disease (BOLD) 
Study 
BOLD Study is a multicenter international study which collects country-
specific data about COPD from subjects aged 40 and older via questionnaires 
and spirometry [2,42,44].  
2.10.3.3 The Latin American Project for the Investigation of 
Obstructive Lung Disease (PLATINO) Study 
PLATINO Study was a population-based, two-phase study that collected data 
from adults aged 40 or older in five urban areas in Latin America. Five centers 
participated during the baseline study in the first phase carried out between 
2002 and 2004 (5315 participants). The follow-up study was performed in 
three centers 5 to 9 years from the baseline study for the first- phase 
participants. Health data were collected and spirometry was performed [106].  
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3. AIMS 
This doctoral study aimed to assess baseline cross-sectional associations 
between obstruction and various factors, to control for those associations, and 
to evaluate whether obstruction predicts all-cause and cause-specific mortality 
and MI during a three-decade follow-up period in a national health 
examination survey representing adult Finns.    
 
The specific aims in studies I to IV were as follows: 
 
 
1. According to previous data, obstruction predicts all-cause mortality by 
decreasing lung function. Our research aimed to determine whether all-
cause mortality in subjects with obstruction varied by GOLD stage, age, 
or sex in a long-term follow-up (study I).  
2. Obstruction appears to predict cardiovascular mortality, yet many 
factors confound the association. In this study, we aimed to evaluate 
whether the GOLD stage or including only those who had no 
cardiovascular disease at baseline affected the association (study I). 
3. Obstruction appears to predict coronary death, but previous studies 
found both positive and negative results about the association between 
obstruction and MI. Our research aimed to determine whether 
obstruction predicts MI and coronary death in a study population 
without a cardiovascular disease at baseline, and whether age, sex, or 
follow-up time affects the associations (study II).  
4. Past TB and obstruction have an association with one another. 
However, only limited long-term follow-up data about whether past TB 
confounds or modifies the association between obstruction and all-
cause mortality. We aimed to evaluate these associations (study III).   
5. A low vitamin D status and obstruction appear to have an association 
with one another, and both predict premature mortality. This study 
aimed to determine whether a low vitamin D status confounds or 
modifies the association between obstruction and all-cause mortality 
(study IV).  
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4 MATERIALS AND METHODS 
4.1 STUDY POPULATION 
The Mini-Finland Health Survey was a national health examination survey 
carried out between 1978 and 1980. During the first stage of sampling, 320 
clusters (including one or more municipalities) were combined to form 40 
nationally representative areas (including one or more clusters) with 40 000 
to 60 000 subjects living within them. The criteria for stratification included 
the proportion of industrial and agricultural populations and the population 
center degree. During the second stage, a systematic sample of 8000 subjects 
(3637 men and 4363 women) was drawn from the areas from the Social 
Insurance Institution’s population registry, where each individual in the 
population had an equal probability of selection. The sample represented the 
Finnish adult population aged 30 or older. During the baseline survey (in 
1978–1980), 7217 subjects participated (90.2% of the sample, 3322 men and 
3895 women). The geographical location of study subjects in the baseline 
survey appears in Figure 2 [48,50,51,109].  
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Figure 2 Geographical location of the Mini-Finland Health Survey study subjects  
 
4.2 SELECTION OF SAMPLE POPULATIONS IN 
STUDIES I TO IV 
In studies I to IV, we included those subjects for whom all the necessary data 
were collected for each study, including spirometry. Subjects with any missing 
data were excluded separately from each study. In addition, subjects with 
asthma were excluded from studies I and III. In study II, we aimed to 
determine whether obstruction at baseline represented an etiological factor for 
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MI or coronary death, and respectively, in the subanalyses for study I whether 
obstruction represented an etiological factor for cardiovascular mortality. 
Therefore, those with diagnosed cardiovascular disease (any heart disease, 
intermittent claudication, or cerebrovascular disease) at the baseline study 
were identified as possible confounders and excluded from those analyses. 
Figure 3 provides a flowchart of the study population in studies I to IV [50,51]. 
 
 
 
Figure 3 Flowchart of the study populations in studies I to IV  
 
4.3 METHODS  
4.3.1 BASELINE EXAMINATION 
A baseline examination elicited the subject’s pertinent health information and 
consisted of a health interview, questionnaires, and a basic health examination 
including laboratory tests and various measurements, such as, blood 
pressures, chest x-ray, and spirometry [48,50,51,109]. 
4.3.2 STANDARD INTERVIEW, BASIC QUESTIONNAIRE, AND 
MEASUREMENTS 
The basic questionnaire provided information on the subject’s general health, 
leisure physical activity, and educational level. General health was categorized 
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as good, moderate, or poor. Leisure physical activity was assessed using 
questions about the duration, intensity, and frequency of physical activity and 
further classified into three categories: inactive (little physical exercise), 
occasionally active (exercise during some hobbies or irregular exercise), or 
regularly active (regular exercise). Educational level was categorized according 
to the number of completed years of schooling: basic (< 8 years), intermediate 
(8–12 years), and higher (> 12 years). 
Height, weight, and blood pressure were measured and an 
electrocardiogram (EKG) was taken using a standardized methodology. BMI 
(weight (kg)/height² (m²)) was calculated as a measure of relative weight 
[48,50,51]. 
Chest radiographs with anteroposterior and lateral views were taken in a 
mobile unit at a constant 120 kilo-voltage power, using automatic exposure 
control, and a 135-cm film focus. The chest radiograph was repeated later if 
the technical quality was low [50]. 
Smoking habits were assessed during a standard interview and study 
subjects were categorized as never-smokers, former smokers, and current 
smokers. Former smokers had quit smoking at least one month preceding the 
baseline survey. Current smokers smoked at least one cigarette, cigar, or pipe 
daily or almost daily during the last year prior to the survey. Current smokers 
were further divided into two groups according to daily smoking behavior: 1 to 
19 and ≥ 20 cigarettes per day [50,51]. 
4.3.3 LABORATORY MEASUREMENTS 
Fasting blood samples were taken during the baseline health examination and 
kept frozen at −20°C until measurement. The plasma glucose concentration 
was determined from blood samples and measured using the glucose oxidase 
method (Boehringer Mannheim, GmbH, Mannheim, Germany). The total 
serum cholesterol and high-density lipoprotein (HDL) cholesterol 
concentrations were analyzed using a direct modification of the Liebermann–
Burchard method [35,50,51]. The concentration of HDL cholesterol was 
measured from the supernatant of the serum after precipitation of low-density 
lipoprotein cholesterol (LDL) and very LDL cholesterol using a 
magnesium/dextran sulphate [124].  
Vitamin D status was determined as the serum 25(OH)D concentration 
using radioimmunoassay (DiaSorin, Inc., Stillwater, MN, USA) in 2003. The 
inter-assay coefficient of variation for 25(OH)D determination was 7.80% at a 
mean level of 47.3 nmol/L (n = 167) and 9.12% at the level of 131.3 nmol/L 
(n = 135). The proportion of quality-control samples was 13.5% [35,125]. For 
analyses, we used the tertiles of the measured 25(OH)D concentrations: 5 to 
32 nmol/L, 33 to 48 nmol/L, and 49 to 180 nmol/L. There was no specifically 
determined concentration for a low vitamin D status. 
The C-reactive protein (CRP) was determined between 2003 and 2005 
using a latex turbido-metric immunoassay (Olympus AU 400 analyzer system 
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for clinical chemistry, Wako Chemicals, Neuss, Germany). The detection limit 
for CRP was 0.06 mg/L. The measured levels of CRP were categorized for 
analyses in this study as follows: 0.04 to 0.99 mg/L, 1.00 to 1.99 mg/L, and ≥ 
2.00 mg/L [50,51].  
4.3.4 SPIROMETRY  
 
Spirometry was performed in the Mini-Finland Health Survey to screen for 
abnormal lung functions and to categorize lung functions according to the 
measured values. The requirements for the spirometry device in the health 
examination survey were that it should be reliable, simple to use, fast, strong, 
light, and in common use. The Vitalograph spirometer (Vitalograph Ltd., 
Buckingham, England) having the best correspondence with these criteria, 
was used in the study [50,126]. 
Spirometry was performed at the baseline according to the manufacturer’s 
guidelines. The measurement quality was controlled during the study.  
Laboratory technicians were specially trained to perform spirometry to ensure 
the quality. The technicians followed the standard guidelines and instructions 
for spirometry, and presented the test procedure individually to each subject. 
The intention was to record for each participant at least two spirometry curves, 
which were as consistent as possible. Subjects were instructed to inhale and 
fill their lungs with air, and, then, to exhale as forcefully and completely as 
possible to reach an adequate and high-quality forced expiratory volume in 1 s 
(FEV1) and forced vital capacity (FVC).  
The highest technically acceptable efforts recorded for the body 
temperature and pressure, saturated with water vapor (BTPS) values of FEV1 
and FVC were reported and FEV1/FVC was estimated by using the highest 
FEV1 and FVC readings. No bronchodilation was performed [50,51,59,127]. 
 
4.3.5 STANDARDIZED PHYSICAL EXAMINATION 
The basic questionnaire included questions about the symptoms of chronic 
disease, a history of any chronic disease diagnosed by a physician, the overall 
health status, and lifestyle factors. Those with any abnormal findings from the 
questionnaires or basic examination were advised to participate in a 
standardized physical examination performed by a specially trained physician 
[48,50,51]. 
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4.4 DEFINITION OF DETERMINANTS  
4.4.1 REFERENCE VALUES FOR OBSTRUCTION  
In studies I to III, the individual results for each subject were calculated 
according to SAPALDIA. In subjects older than 75, the statistical formulae for 
the SAPALDIA reference values biased the values [56,62]. Therefore all such 
subjects were assumed to be 75 years old in the statistical formulae. In studies 
II and IV, obstruction was determined using the international GLI reference 
values based on the values for Caucasians [58].  
4.4.2 CLASSIFICATION OF OBSTRUCTION  
Four different definitions for obstruction were used in studies I to IV: those 
with a fixed cut-off limit (FEV1/FVC < 0.7) and with either GOLD stages 1–4 
(study 1) or GOLD stages 2–4 (study I) or with FEV1/FVC < LLN according to 
SAPALDIA (studies I and III) or GLI (studies II and IV), categorized as having 
an obstruction; all others did not [1,3]. The LLN categorization for each subject 
was calculated using an individual LLN value for obstruction corresponding to 
the age, sex, and height of the subjects [56,58]. In studies I and III, the degree 
of obstruction was further classified into GOLD stages 1–4 (Figure 1, Table 3) 
[1,3]. 
4.4.3 CARDIOVASCULAR DISEASES, DIABETES, AND ASTHMA 
A field physician diagnosed cardiovascular diseases, diabetes, and asthma on 
the basis of all available information; therefore, no data were missing for the 
diabetes and baseline cardiovascular disease categories for any subjects. In 
studies I and II, the category of baseline cardiovascular disease included any 
diagnosed heart disease, intermittent claudication, or cerebrovascular disease 
[50]. Subjects were determined to have diabetes if they had a self-reported 
history of diagnosed diabetes and were treated by a physician for diabetes, if 
they had a fasting plasma glucose level ≥ 6.7 mmol/L, or both [48,50,51]. 
Asthma was indicated if a physician previously diagnosed asthma, if the 
subject received medication for asthma, or if the subject was under current 
physician treatment for asthma [3,48,50,51]. 
4.4.4 PAST TB 
In this study, only past pulmonary tuberculosis (TB) was analyzed. The basic 
questionnaire elicited TB history through the following questions: “Have you 
had, according to a physician’s diagnosis, pulmonary (lung) TB? Have you ever 
been hospitalized for it? Have you ever received medications for it [50]? ” 
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Chest x-rays were taken during the baseline survey in a transferable 
radiological unit of the Mobile Clinic at all 40 study places and analyzed by two 
experienced radiologists who assessed independently of each other the scars 
or local fibrosis representing earlier TB on a chest x-ray. The computed kappa 
coefficient for the radiologists’ diagnostic agreement among subjects without 
a TB disease history was 0.49 [95% confidence interval (95% CI) 0.45–0.52, 
McNemars’ s test for systematic difference, p = 0.0026] [48,50,128].  
According to this data, past TB was categorized hierarchically as: a TB 
indicative scar on a chest x-ray identified by one or both radiologists (no TB 
treated in hospital and no history of TB medications), a disease history (TB 
treated in hospital or with TB medications), past TB (either a TB disease 
history or a radiological scar), and no TB. The category of no TB included 
subjects with neither a TB disease history nor a scar on a chest x-ray. 
4.5 FOLLOW-UP 
After the baseline examination, it was possible to follow the study population 
through various registers using the subject’s social security number to track 
participants. For this study, the study population’s register data were 
continuously followed-up through Statistics Finland (causes of death, Study 
I–IV) and through the Hospital Discharge Registers (Study II) [49,129].  
Mortality in the cohorts was followed for studies I to IV from Statistics 
Finland using the subjects’ individual identification numbers to track 
participants according to the eighth, ninth and tenth editions of the 
International Classification of Diseases (ICD-8, ICD-9, and ICD-10, 
respectively) based on the baseline examination through 31 December 2008 
in study I, 2011 in studies III and IV, and 2013 in study II [49]. In studies I 
through IV, all-cause mortality included all deaths in the study population 
during the follow-up periods. 
In study I, outcomes from of cardiovascular mortality included coronary 
heart disease (ICD codes 410–414 in ICD-8 and ICD-9 and I20–I25 in ICD-
10) and cerebrovascular deaths due to subarachnoid hemorrhage (430 in ICD-
8 and ICD-9 and I60 in ICD-10), hemorrhagic stroke (431 in ICD-8 and ICD-
9 code and I61 in ICD-10), ischemic stroke (433–434 in ICD-8 and ICD-9 
codes and I63 in ICD-10), or other unspecified cerebrovascular causes (435–
438 in ICD-8, 432 and 435–438 in ICD-9, and I62 and I64–I69 in ICD-10). 
In study II, subjects were followed for three different endpoints (until any 
of the following occured first): date of hospitalization for MI, death, or through 
31 December 2013. Diagnoses for hospital care periods were followed from the 
National Care Register for Health Care according to ICD-8, ICD-9, and ICD-
10, respectively. This registry is a nationwide obligatory automated database 
containing the hospital discharge diagnosis codes for all medical admissions 
maintained by the Finnish National Institute for Health and Welfare [49,129]. 
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In study II, the endpoint of MI included hospital care periods registered 
using ICD codes 410 (ICD-8 and ICD-9) and I21 and I22 (ICD-10). A major 
coronary event necessitating hospital care periods registered using ICD codes 
410 and 411.0 (ICD-8 and ICD-9) and I20.0, I21, and I22 (ICD-10), 
undergoing coronary artery bypass graft surgery (CABG) or angioplasty, or the 
cause of death listed by using ICD codes 410–414 and 798 (but not 798.0A) 
(ICD-8 and ICD-9) and I20–I25, I46, R96, and R98 (ICD-10) were included. 
Coronary death in study II included cause of death registered using ICD codes 
410–414 and 798 (but not 798.0A) (ICD-8 and ICD-9) and I20–I25, I46, R96, 
and R98 (ICD-10). 
The long-term persistence of obstruction was analyzed among 905 
participants from the baseline Mini-Finland Health Survey who were re-
examined at the next national health examination survey, Health 2000 [111]. 
According to the fixed cut-off limit (FEV1/FVC < 0.7), 12 subjects had 
obstruction at baseline; after 21 to 23 years, 9 of these had persistent 
obstruction, while 3 did not. 
4.6 MODELS 
The models were constructed based on previous studies, the aims of each 
study, and our research group’s analyses of the Mini-Finland Health Survey 
data.  
Obstruction at baseline was examined by predicting the all-cause, 
cardiovascular (study I) and coronary mortality, respectively, and MI and a 
major coronary event (MI or coronary mortality, whichever occurred first) 
(study II). Factors which had shown an association with cardiovascular 
diseases in previous studies were entered into multivariate models as potential 
confounders: age, sex, smoking, BMI, educational level, leisure physical 
activity, general health, diabetes, diastolic and systolic blood pressure, and 
serum total and HDL cholesterol concentrations. 
    Study III focused on the associations between obstruction, past TB, and all-
cause mortality. Multivariate models were adjusted for those factors which 
had shown associations with obstruction, past TB, and all-cause mortality in 
previous studies or in the current study. Factors such as age, sex, smoking, 
BMI, general health, leisure physical activity, and educational level were 
included in the model. Past TB was also analyzed as a potential effect modifier. 
    In study IV, our research group evaluated the associations between 
obstruction, a low vitamin D status, and all-cause mortality. Multivariate 
models were adjusted for factors which had shown an association with 
obstruction, vitamin D status, and all-cause mortality in previous studies 
[35,130,131] or in the current study. Factors such as age, sex, smoking, 
educational level, leisure physical activity, BMI, CRP, and asthma were 
included. Vitamin D status was also analyzed as a potential effect modifier. 
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4.7 STATISTICAL METHODS 
Cross-sectional associations between obstruction and various baseline 
characteristics were analyzed through logistic regression. The results were 
expressed as adjusted odds ratios (ORs) with 95% confidence intervals (CIs). 
The Cox’s proportional hazards regression model was used to estimate the 
strength of the association between obstruction and various endpoints during 
follow-up. The adjusted hazard ratios (HRs) with 95% CIs were estimated. 
Two main models were constructed in studies I to IV: adjusted for age and sex 
(and in some cases, for smoking as well, model 1) and adjusted for factors 
considered potential confounders in each study (a multivariate model, model 
2). In this thesis, the most important results are reported from the analyses 
including the entire study population or a specific subpopulation. The effect 
modification was studied by entering multiplicative first-degree interaction 
terms one-by-one into the Cox’s model for each study. The statistical 
significance of the interactions was tested using a likelihood ratio test in 
studies I, III, and IV and with the Wald’s test in study II. Analyses related to 
studies I, III, and IV were performed using SAS System for Windows (SAS 
Institute, Inc., Cary, NC, USA, versions 9.1, 9.2, and 9.3) and using IBM’s SPSS 
(version 23 and 24) for studies II and IV.  
 
4.8 ETHICAL CONSIDERATIONS  
The Mini-Finland Health Survey predated current legislation on ethics in 
medical research. However, all participants were fully informed about the 
study, they participated voluntarily, and the use of their information for 
medical research was explained to them. Agreeing to participate in the 
baseline health examination was understood to indicate informed consent. 
Statistics Finland approved the linkage of national mortality data to the survey 
data used here [49]. 
According to a statement from the Medical Ethics Committee of the 
Hospital District of Helsinki and Uusimaa in Finland (June 2013), this 
doctoral study does not fall under the purview of laws regarding medical 
research. Thus, the study protocol does not violate any ethical considerations 
or standards. 
Results 
42 
5 RESULTS  
5.1 OBSTRUCTION IN STUDIES I TO IV 
Obstruction was determined in studies I to IV by applying two different 
reference values and the four definitions. The prevalence of obstruction at 
baseline varied from 3.4% to 4.7% (Table 3). 
Table 3 Prevalence of obstruction in study I to IV populations using different reference 
values and definitions of obstruction and the incidence of all-cause mortality in 
subjects with and without obstruction during various follow-up periods. 
 Follow-up 
time until 
Reference 
values Definition for obstruction Total (n)² Death (n)³ 
Study I 31 Dec 2008 SAPALDIA FEV1/FVC ≥ 0.7 or FEV1/FVC < 0.7, GOLD 1 6338 (95.3%) 2895 (45.7%) 
   FEV1/FVC < 0.7, GOLD 2–4 298 (4.5%) 273 (91.2%) 
   FEV1/FVC < 0.7, GOLD 1 165 (2.5%) 133 (80.6%) 
   FEV1/FVC < 0.7, GOLD 2 213 (3.2%) 192 (90.1%) 
   FEV1/FVC < 0.7, GOLD 3 72 (1.1%) 68 (94.4%) 
   FEV1/FVC < 0.7, GOLD 4 13 (0.2%) 13 (100%) 
   FEV1/FVC ≥ LLN 6407(96.6%) 2981 (46.5%) 
   FEV1/FVC < LLN 231 (3.4%) 188 (81.3%) 
   FEV1/FVC < LLN, GOLD 1 46 (0.7%) 22 (47.8%) 
   FEV1/FVC < LLN, GOLD 2 108 (1.6%) 93 (86.1%) 
   FEV1/FVC < LLN, GOLD 3 65 (1.0%) 61 (93.8%) 
   FEV1/FVC < LLN, GOLD 4 12 (0.2%) 12 (100%) 
Study II 31 Dec  2011 SAPALDIA FEV1/FVC ≥ LLN 5413 (97.1%) 2396 (44.3%) 
   FEV1/FVC < LLN 163 (2.9%) 121 (74.2%) 
  GLI FEV1/FVC ≥ LLN 5366 (96.2%) 2366 (44.1%) 
   FEV1/FVC < LLN 210 (3.8%) 151 (71.9%) 
Study III 31 Dec 2013 SAPALDIA FEV1/FVC ≥ LLN 6466 (96.5%) 3625 (56.1%) 
   FEV1/FVC < LLN 235 (3.5%) 199 (84.7%) 
   FEV1/FVC < LLN, GOLD 1 47 (0.7%) 24 (51.1%) 
   FEV1/FVC < LLN, GOLD 2 112 (1.7%) 101 (90.2%) 
   FEV1/FVC < LLN, GOLD 3 64 (1.0% 62 (96.9%) 
   FEV1/FVC < LLN, GOLD 4 12 (0.2%) 12 (100%) 
Study IV 31 Dec 2011 GLI FEV1/FVC ≥ LLN 6365 (95.3%) 3283 (51.6%) 
   FEV1/FVC < LLN 311 (4.7%) 247 (79.4%) 
¹ Study populations were defined separately for studies I to IV including those with all necessary 
data for each study. From the study II population, subjects with a cardiovascular disease diagnosed 
at baseline study were excluded.  
² Number and percentage of subjects with and without obstruction in study I to IV populations.  
³ Number and percentage of subjects with and without obstruction who died during follow-up  
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The overlapping between obstruction and asthma was evaluated in the 
study II population using the SAPALDIA and GLI reference values. According 
to SAPALDIA, there were 163 subjects with only obstruction, 86 with only 
asthma (diagnosed at baseline), and 14 with both asthma and obstruction 
(Kappa 0.094). According to GLI, there were 191 subjects with only 
obstruction, 67 with only asthma, and 19 with both asthma and obstruction 
(Kappa 0.109). Using the GLI reference values in subjects aged 30 to 49, we 
identified 30 with only obstruction, 7 with asthma, and 3 with both asthma 
and obstruction (Kappa 0.018). 
 
5.2 BASELINE CHARACTERISTICS IN THE MINI-
FINLAND HEALTH SURVEY 
The distributions of the baseline characteristics and the number of missing 
values among all 7217 subjects who participated in the baseline study appear 
in Table 4. No data were missing for age, sex, diabetes, and cardiovascular 
disease at baseline. Baseline characteristics for studies I to IV can be found in 
the articles attached at the end of this thesis. 
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Table 4 Baseline characteristics in the Mini-Finland Health Survey study population (n = 
7217) and the number of subjects with missing values for each characteristic.  
 
Characteristics 
Mean and standard 
deviation (SD) or 
prevalence 
Data missing 
Age (years) 51.3, ±14.2  
Women 3322 (46.0%)  
Smoking  10 
   Never-smoker 3999 (55.5%)  
   Former smoker 1505 (20.9%)  
   Current smoker, 1–19 
cigarettes/ day 1062 (14.7%)  
   Current smoker, ≥20    
cigarettes/day 641 (8.9%)  
FEV?/FVC (%)¹ 80.1, ±7.5 209 
Asthma 136 (1.9%) 22 self-reported, 54 clinical diagnosis² 
General health  9 
   Good 3377 (46.9%)  
   Moderate 2673 (37.1%)  
   Poor 1158 (16.1%)  
Leisure physical activity  10 
   Inactive 2636 (36.6%)  
   Occasionally active 3477 (48.2%)  
   Regularly active 1094 (15.2%)  
Educational level  20 
   Basic (<8 years) 4885 (67.8%)  
   Intermediate (8–12 years) 1506 (20.9%)  
   Higher (>12 years) 806 (11.2%)  
Diabetes 412 (5.7%)  
BMI (kg/m²) 25.9, ±4.1 13 
Systolic pressure (mmHg) 146.4, ±24.0 6 
Diastolic pressure(mmHg) 87.3, ±11.8 6 
Fs-cholesterol (mmol/L) 7.0, ±1.4 3 
Fs-HDL cholesterol (mmol/L) 1.7, ±0.4 6 
Past TB3  93 
   No TB 5836 (81.9%)  
   One radiologist observed3 652 (9.2%)  
   Two radiologists observed3 403 (5.7%)  
   Disease history4 233 (3.3%)  
Vitamin D status (nmol/L)? 42.9, ±19.6 147 
CRP (mg/L) 6 2.5, ±4.7 268 
Baseline cardiovascular disease7 1418 (19.7%)  
¹ FVC: mean 4.05, SD ±1.2, data missing for 205 subjects; and FEV?: mean 3.3 l/s, SD ±1.0, data 
missing for 208 subjects.  
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² Number of subjects with missing data for a self-reported history of asthma and clinical diagnosis 
of asthma at baseline survey. 
³ A scar or local fibrosis on a chest x-ray observed by one or both radiologists in the Mini-Finland 
Health Survey, excluding those with TB treated in hospital or prescribed TB medications.  
? TB treated in hospital or prescribed TB medications.  
? Concentration of 25(OH)D.  
6 Concentration of serum C-reactive protein.  
7 Subjects with any heart disease, intermittent claudication, or cerebrovascular disease diagnosed 
at baseline. 
 
5.3 ALL-CAUSE MORTALITY, CAUSE-SPECIFIC 
MORTALITY, AND MI 
We analyzed data for 6636 participants in study I and 5567 participants in 
study II where those with cardiovascular disease at baseline were excluded. 
Obstruction, with a increasing GOLD stage, predicted all-cause mortality 
during follow-up in study I (Figure 4).  
 
 
Figure 4 Obstruction and all-cause mortality by GOLD stage 1–4 during follow-up from 
1978–1980 through 31 December 2008. 
Obstruction predicted all-cause mortality for both sexes in all age groups 
(30–49, 50–69, and ≥ 70 years), but the difference between subjects with and 
without airway obstruction was more pronounced in men and women aged 30 
to 49 at baseline in study I population (Figure 5).    
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Figure 5 Obstruction and all-cause mortality in women and men aged 30–49 at baseline 
in a follow-up study from 1978–1980 through 31 December 2008. 
In study I, 1573 deaths (49.7% of all deaths) resulted from cardiovascular 
causes. We found a strong association between GOLD stage and 
cardiovascular mortality in an age-, sex-, and smoking (Figure 6) and in a 
multivariate adjusted model. Respectively, HRs with 95% CIs for GOLD stages 
1 to 4 were 1.35 (1.06–1.72), 1.34 (1.09–1.65), 1.20 (0.83–1.72), and 1.27 (0.47–
3.40) in a multivariate analysis when those without obstruction were used as 
the reference. Yet, we found no clear-cut association after those subjects with 
cardiovascular disease at baseline were excluded from the analysis. 
Respectively, HRs with 95% CIs from GOLD stages 1 to 4 in an age-, sex-, and 
smoking adjusted model were 1.22 (0.84–1.78), 1.46 (1.05–2.04), 1.49 (0.87–
2.56), and 2.21 (0.31–15.85), and 1.32 (0.90–1.92), 1.34 (0.95–1.88), 1.37 
(0.79–2.37), and 2.03 (0.28–14.67) in a multivariate adjusted model. Those 
without obstruction were used as the reference value. The multivariate model 
was adjusted for age, sex, smoking, general health, leisure physical activity, 
educational level, diabetes, BMI, total and HDL cholesterol, and systolic and 
diastolic blood pressure. 
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Figure 6 Obstruction and cardiovascular mortality for GOLD stages 1–4 in a follow-up 
study from 1978–1980 through 31 December 2008. 
Obstruction predicted coronary mortality, but not MI or a major coronary 
event in a multivariate model during follow-up for those without 
cardiovascular disease at baseline in the study II population (Figure 7).  
 
 
Figure 7 Obstruction and MI, a major coronary event, and coronary death in a 
multivariate model among those without cardiovascular disease at baseline (n = 
5567 subjects) from 1978–1980 through 31 December 2011. 
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Obstruction predicted MI, a major coronary event, and coronary death 
during follow-up in subanalysis among women aged 30 to 49 years at baseline 
in the study II population (Figure 8).  
 
 
Figure 8 Obstruction and MI, a major coronary event, and coronary death among women 
without diagnosed cardiovascular disease aged 30–49 at baseline in a follow-up 
study from 1978–1980 through 31 December 2011. 
 
5.4 PAST TB AND ALL-CAUSE MORTALITY 
Among 6701 subjects in study III, 1191 (17.8%) had past TB including a TB 
disease history or a TB indicative scar on a chest x-ray. In a cross-sectional 
study, those with past TB were more often former or current smokers, men, 
had a poorer general health, and a lower educational level compared to the 
entire study population. Past TB and obstruction had an association in a cross-
sectional study, and none of the baseline characteristics modified the 
association between past TB and obstruction (Figure 9). 
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Figure 9 The cross-sectional association at baseline between obstruction and TB history.  
There were 3824 (57% of the population) deaths during the follow-up 
period. A TB disease history did not predict all-cause mortality, although scars 
observed on a chest x-ray and obstruction did, both independently of each 
other and independently of the confounding factors. HRs with 95% CIs for all-
cause mortality among those with past TB reached 1.10 (1.00–1.21) in a 
multivariate model when a scar was noted by one radiologists, 1.17 (1.04–1.32) 
when noted by two radiologists, 1.01 (0.86–1.20) when there was a disease 
history, and 1.11 (1.03–1.20) when there was any past TB (those without TB 
were used as the reference value). A multivariate model was adjusted for age, 
sex, smoking, BMI, physical activity, education, and general health. 
Past TB and obstruction had an additive joint effect on all-cause mortality 
(Figure 10). Neither past TB nor obstruction had a modifying or confounding 
effect on the association with the other for all-cause mortality.   
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Figure 10 Joint effect of past TB and obstruction on all-cause mortality in a follow-up study 
from 1978–1980 through 31 December 2013. 
 
5.5 VITAMIN D STATUS AND ALL-CAUSE 
MORTALITY 
Study IV consisted of 6676 subjects. The mean 25(OH)D concentration was 
43.4 nmol/L (SD ±19.5) for the entire study population and 39.1 nmol/L (SD 
±18.8) among subjects with obstruction. We found a significant cross-
sectional association between obstruction and a low vitamin D status at 
baseline in a model adjusted for age, sex, and smoking, but not in a 
multivariate model also adjusted for asthma, educational level, leisure 
physical activity, BMI, and CRP (Figure 11). 
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Figure 11 Cross-sectional association at baseline between obstruction and vitamin D status.  
During follow-up, 3530 subjects (52.9% of the population) died. 
Obstruction and a low vitamin D status predicted all-cause mortality 
independently of each other in a multivariate model (Figures 12 and 13).  
 
 
 
Figure 12 The association between obstruction and all-cause mortality in a follow-up study 
from 1978–1980 through 31 December 2011.  
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Figure 13 The association between vitamin D status and all-cause mortality in a follow-up 
study from 1978–1980 through 31 December 2011.  
 
Vitamin D status did not affect the association between obstruction and all-
cause mortality. Yet, a statistically significant interaction between obstruction 
and vitamin D status was found (p = 0.007). In subjects without obstruction, 
HRs from the lowest to the highest vitamin D status in tertiles were 1.00, 0.96 
(0.87–1.05), and 0.89 (0.81–0.98), and 1.00, 0.96 (0.71–1.31), and 0.57 
(0.40–0.80), respectively, in subjects with obstruction, in a multivariate 
model.  
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6 DISCUSSION 
Our research group followed a national health examination cohort 
representative of Finnish adults for more than three decades. Obstruction 
predicted all-cause mortality by increasing GOLD stage and appeared 
detrimental especially when observed among subjects 30 to 49 years old. 
Additionally, obstruction predicted coronary mortality but not MI. Past TB 
and obstruction had an additive effect on all-cause mortality during follow-up. 
A low vitamin D status among subjects with obstruction in particular appears 
to predict premature death.   
 
6.1 OBSTRUCTION AND MI AND CORONARY, 
CARDIOVASCULAR, AND ALL-CAUSE 
MORTALITY 
6.1.1 ALL-CAUSE MORTALITY 
In this study, our group found that obstruction predicted all-cause mortality 
according to the GOLD stage. This was consistent with previous studies 
[1,13,15-17,67,68]. 
In this study, age at baseline significantly modified the association between 
obstruction and all-cause mortality: it was strongest among men and women 
aged 30 to 49. A Danish study found a significant all-cause mortality trend 
among those with an obstruction at ≤ 45 years, and, similarly, a study from the 
USA reported that a lower FEV1 at the age of 21 to 35 predicted all-cause 
mortality during follow-up times of 16–21 years and 33 years [15,132], 
respectively. Smoking is the main risk factor for COPD in Europe also among 
subjects aged 20 to 44 [133]. Therefore, in particular, smokers who develop 
obstruction at a younger age might have an increased mortality risk. 
According to recent studies, the prevalence of smoking in Finland is 
decreasing among younger age groups as evidenced in one study among those 
under 18 years old and in another study among Finns aged 25 to 54. If this 
positive trend continues, the prevalence of obstruction may decrease in future. 
In the USA, a decrease in age-adjusted prevalence and mortality due to COPD 
among men has already been reported. However, in Finland, there was no 
change in the prevalence of COPD between the Mini-Finland Health Survey 
and the Health 2000 Survey, and the prevalence of smoking appear to increase 
among subjects aged 55 to 64. The increasing use of electronic cigarettes 
among subjects under 18 in Finland represents a concerning trend [3,134-
136]?  
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6.1.2 CARDIOVASCULAR MORTALITY  
In this study, we found that obstruction predicted cardiovascular mortality 
already for GOLD stage 1 while the risk was constant for GOLD stages 1–4 in 
age-, sex-, and smoking- and multivariate adjusted models. However, after 
excluding from the analysis those with a cardiovascular disease diagnosed at 
baseline, there was no association in these same models. 
According to previous data, COPD and cardiovascular mortality both have 
association with decreasing lung function [13,18,65,71,76]. In a case–control 
study, COPD emerged as a risk factor for cardiovascular mortality [76], and a 
reduced FEV1 predicted cardiovascular mortality even among never-smokers 
[65]. Subjects with mild to moderate COPD died more from cardiovascular 
diseases while those with more severe disease died from respiratory failure 
[13,19]. However, why in our material there was no significant increase in 
cardiovascular mortality among subjects without any cardiovascular disease 
at baseline remains unresolved. 
6.1.3 CORONARY MORTALITY AND MI 
In the current follow-up study, obstruction predicted coronary mortality but 
not MI except in the subgroup of younger women. According to earlier data, 
prevalent COPD and MI appear to predict all-cause mortality, while prevalent 
COPD predicts coronary mortality, also during long-term follow-up 
[15,18,22,79]. Yet, most studies on the association between COPD and 
coronary mortality were performed with shorter follow-up periods, among 
hospital patients, or with minor adjustments [9-11,15]. However, the 
multivariate adjusted results with the long-term follow-up in this study 
supported these previous findings. 
Most studies found about COPD and MI were not directly comparable to 
the Mini-Finland Survey data since they were register-based, cross-sectional, 
included limited adjustments, or were performed for cohorts of hospital 
patients (Table 2). Yet, in the referenced studies, COPD predicted MI in two 
register-based and case-control studies [11,84-86], but not in one case-control 
study [83]. The cross-sectional studies reported both an association 
[22,74,81,85,87] or no association [75,82].  
In the current follow-up study, obstruction predicted MI in the subgroup 
of women aged 30 to 49. In previous studies, the youngest subjects with COPD 
(aged < 45 or < 50 or 40–64) had a particularly increased risks of MI, fatal MI, 
coronary heart disease, and coronary mortality [15,74,84,85], while 
obstruction predicted coronary mortality more significantly among women 
under 45 years [15]. Additionally, impaired lung function at a younger age (16–
35 or 21–35 years) predicts increased total, cardiovascular, heart, and 
cardiopulmonary mortality [132,137]. Furthermore, coronary heart disease 
appears different in men and women; in women, coronary heart disease 
concentrates among older populations, while younger women more often 
suffer fatal MI [138,139].   
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6.1.4 CARDIOVASCULAR DISEASES 
Obstruction appears to have association differently with cardiovascular 
diseases compared to the disease’s classic risk factors. These risk factors 
include for instance smoking, high LDL cholesterol, and hypertension, which 
have association with the risk for various cardiovascular diseases and deaths 
from them, including the endpoints analyzed in this study—that is, MI and 
coronary and cardiovascular death [140-145]. 
Previously, obstruction predicted cardiovascular diseases and 
cardiovascular and coronary mortality, although the association between 
obstruction and the risk of MI and stroke varied [8-11,15,18,22,79]. In our 
study, baseline cardiovascular disease appears significant for the association 
between obstruction and the cardiovascular endpoints analyzed. Obstruction 
predicted coronary death in a multivariate-adjusted model after those with 
baseline cardiovascular disease were excluded, but not cardiovascular 
mortality. The association between obstruction and MI was significant only in 
the subgroup analyses. No clear-cut inference could be made on the basis of 
this epidemiological study.  
The associations between COPD and coronary and cardiovascular diseases 
appear complicated. Inflammatory reactions running behind these diseases 
might account for part of these conflicting results [1,20,22,23,82,146]. 
Additionally, the effect of hypercholesterolemia, hypertension, diabetes, and 
smoking as risk factors for cardiovascular diseases also appears partly induced 
by endothelium dysfunction caused by inflammatory reaction [146]. In 
addition, COPD and cardiovascular diseases share many risk factors such as 
smoking, ageing, and a low socioeconomic status; and both diseases and these 
associating factors predict chronic diseases and mortality complicating the 
further evaluation of these associations [1,8,9,12-14,147,148]. In general, it 
appears that obstruction may be involved in the prognosis rather than the 
etiology of cardiovascular diseases.   
 
6.1.5 CONCLUSIONS: MI AND CORONARY, CARDIOVASCULAR, 
AND ALL-CAUSE MORTALITY 
To summarize, obstruction predicts all-cause mortality; specifically, younger 
subjects with obstruction appear to have an increased all-cause mortality risk. 
Additionally, obstruction predicts coronary mortality, but not MI. However, 
younger women with obstruction might have an increased risk of MI.  
 
6.2 PAST TB 
This study revealed a cross-sectional baseline association between obstruction 
and past TB, and the association was stronger among those with a TB disease 
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history compared to those only with a TB indicative scar. These results 
corroborate previous findings [36,39-41,53,93].  
In Danish and Norwegian studies, past TB, defined as a disease history or 
a TB indicative scar on a chest x-ray, predicted all-cause mortality in a long-
term follow-up (materials were comparable with the Mini-Finland Health 
Survey data)  [98,99]. In this study, a TB disease history did not predict all-
cause mortality, but a TB indicative scar did. This apparently resulted from the 
low statistical power–that is, the Mini-Finland survey material included too 
few cases with a TB disease history for a significant result. A TB indicative scar 
predicted all-cause mortality possibly coincidentally; in addition, some 
observed scars were likely caused by diseases other than past TB, while the 
scars observed on subjects in the Mini-Finland Health Survey were not studied 
further. Moreover, we found that past TB and obstruction together predicted 
all-cause mortality through an additive pattern. 
One particular strength in this study lies in that both experienced 
radiologists had previously participated in the x-ray screenings served for the 
entire Finnish population from the 1940s to 1990 [31]; furthermore, they both, 
independent of each other, analyzed all of the x-rays in the Mini-Finland 
Health Survey. Their reliability for diagnosing a TB indicative scar from a chest 
x-ray was evaluated and a moderate kappa was found, equating with an 
overestimation of TB diagnoses. Therefore, the diagnoses made by one or both 
radiologists were analyzed separately.  
According to previous data, two experienced doctors could reliably 
diagnose TB on a chest x-ray if they had diagnostic agreement and the 
diagnostic reliability increased with a high TB incidence [149,150], as it was  
the case at the time of the Mini-Finland Health Survey [31-33]. 
To summarize, a TB disease history and a TB indicative scar on a chest x-
ray have an association with obstruction, including among never-smokers. 
Past TB and obstruction predict all-cause mortality with an additive pattern. 
6.3 ROLE OF VITAMIN D STATUS 
Previous studies reported both an association and no association between a 
low vitamin D status and COPD. These conflicting results may be at least partly 
explained by the complex association between vitamin D metabolism, COPD, 
and multiple confounders [28,45,101]. At least in this study, the association 
between a low vitamin D status and obstruction was primarily attributed to 
confounding variables; a significant association in an age and sex adjusted 
model became non-significant in a multivariate model. 
The complex association between a low vitamin D status and COPD 
complicates determining whether a low vitamin D status affects mortality in 
subjects with COPD [28,45,101]. In a literature review, only three previous 
studies analyzed the associoation between a low vitamin D status and all-cause 
mortality among subjects with COPD in a long-term follow-up study (10 to 18 
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years) [105,107,108]. Two studies showed no association [107,108], although 
in another study, a 25(OH)D concentration < 25 nmol/L had an association 
with all-cause mortality in subjects with a normal lung function [107]. The 
third study reported an association between a low vitamin D status and all-
cause and cardiovascular mortality in subjects with COPD, yet the association 
was primarily attributed to cardiovascular risk factors. In that study, the limit 
for the lowest vitamin D status tertile was < 50.9 nmol/L [105], a level quite 
high compared to the Mini-Finland Health Survey data.  
In this material, obstruction and a low vitamin D status predicted all-cause 
mortality independently of each other, although a low vitamin D status showed 
a stronger association with all-cause mortality in subjects with obstruction 
than in other subjects. Yet, the Mini-Finland Health Survey data have a low 
power, thus indicating the need for replication among a larger cohort before 
drawing any firm conclusions.  
In brief, the baseline association between a low vitamin D status and 
obstruction was largely explained through confounding factors. We found that 
both a low vitamin D status and obstruction had an association with premature 
mortality, although the predictive strength of a low vitamin D status appears 
more pronounced in subjects with obstruction 
 
6.4 REFERENCE VALUES AND DEFINITIONS OF 
OBSTRUCTION 
No single definition for obstruction is in international scientific use; therefore, 
defining obstruction was problematic. International recommendations, 
definitions, and reference values for obstruction varied between 2010 and 
2018 when this study was performed [1,54-56,58,63], and each study used the 
recommended definition that appeared most reasonable at that time or the 
definition recommended by referees.  
Using different definitions for obstruction means that the results from 
studies I to IV were not directly comparable. For instance, the study I 
population included 463 subjects with FEV1/FVC < 0.7 and 231 subjects < 
LLN, and respectively, 406 and 188 deaths in these groups. In comparison, the 
study II population consisted of 163 subjects with obstruction according to 
SAPALDIA < LLN and 210 according to GLI < LLN, and, respectively, 121 and 
151 deaths in these groups. The same concern pervades the referenced studies 
which relied on various definitions and reference values for COPD (GOLD, 
LLN, register data with variable COPD definitions, or other; and SAPALDIA, 
GLI, or other reference values). In a previous study, the COPD prevalence was 
greater with a fixed cut-off limit compared to LLN, and the group falling in 
between these definitions appeared to have an increased risk for 
hospitalization and all-cause mortality [151].  
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The multi-ethnic GLI reference values are quite novel and validation of GLI 
in clinical use is currently taking place in various countries [58,63,152-154]. In 
Scandinavia, GLI appears valid in Norway, but not in Sweden or Finland. In 
the Finnish population, GLI and a fixed cut-off limit (FEV1/FVC < 0.7) 
overestimate obstruction, while SAPALDIA has the best agreement with 
Kainu’s reference values validated for clinical use in the Finnish population 
[56,57,61,152,154]. However, GLI appears to be a rational tool for 
international scientific use to produce internationally comparable data as well 
in the Finnish population. 
Unfortunately, there were no follow-up data about subjects’ COPD 
symptoms and exacerbations in this survey. Therefore, the GOLD’s ABCD 
groups, recommended for clinical use from 2011, could not be used [1,55]. 
However, this doctoral study primarily focused on mortality. The GOLD stages 
1–4 appear to predict all-cause mortality similarly [155,156] or even better 
compared to the ABCD groups [66,106], while the ABCD grouping appears to 
represent an improvement on phenotyping COPD and predicting 
exacerbations [155].  
6.5 STRENGTHS  
In studies I to IV, a representative Finnish adult sample population was 
followed continuously for 30 to 35 years through a national health 
examination survey. Featuring 90% participation rates at the baseline survey, 
specially trained and experienced professionals performed examinations 
using standardized methods [48,50,51]. The Mini-Finland Health Survey 
material consisted of a quite homogenous population with fewer confounders 
compared to the current Finnish population [32,33,48,110,157]. Additionally, 
the causes and dates of death were obtained from the death certificates as 
documented by the attending physicians [49,51]. The National Care Register 
for Health Care data is validated for MI patients [158]. 
When this data was collected in 1970s, TB incidence remained at high level 
in Finland, comparable with the current situation in developing countries 
[31,33], allowing our findings about past TB to remain relevant. The naturally 
low vitamin D status represents a particular strength of this material: when 
the material was collected, no vitamin D fortification was in use and working 
outside under the sun during the summertime was common [48,51]; vitamin 
D supplements complicate and confound analysis in more recently collected 
data [28,45,101,130]. 
6.6  LIMITATIONS  
The study population included over 7000 subjects, yet, the low power emerged 
as the primary limitation; the limited number of subjects with obstruction 
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prevented analysis of factors such as the degree of obstruction, sex, age, and 
specific causes of death more precisely. Thus, the statistical power for 
subanalyses remained weak. 
No bronchodilation was performed, and, therefore, some reversible 
obstruction might have been misclassified as chronic, although obstruction 
appeared to persist among those subjects who had obstruction during the 
Mini-Finland Health Survey baseline examination and were reanalyzed in the 
Health 2000 Survey. In the USA, COPD’s prevalence varied from 20.9% (pre-
bronchodilation values with a fixed cut-off limit for obstruction) to 10.2% 
(post-bronchodilation values with LLN) [159], yet pre- and post-
bronchodilation lung functions appears to comparable predict all-cause 
mortality [160]. However, this deficiency was considered and in thesis was 
used a definition of obstruction when referring to our results and COPD when 
referring to others.  
The Vitalograph spirometer used in the Mini-Finland Health Survey was at 
that time a commonly used device with an analog X-Y writer [50,126]. Yet, the 
accuracy of these spirometers differ from the modern digital flow-capacity 
spirometry devices used in recent decades [57,161]. Additionally, the first 
standard guidelines for spirometry were published in 1979, and, therefore, 
could not be applied in the Mini-Finland Health Survey, potentially affecting 
the quality of spirometry [127,161]. Yet, the spirometry results in the Mini-
Finland Health Survey were reported according to the 1979 guidelines 
[50,127].  
No information about lifetime pack-years smoked was collected. Thus, this 
parameter could not be analyzed. Smoking habits have changed in the Finnish 
population during the follow-up period–in the Mini-Finland Health Survey, 
37.5% of men smoked (aged 30–74), 34.3% (aged 30–74) in the Health 2000 
Survey and 25.2% (aged 25–64) in the 2012 follow-up survey. The comparable 
figures for women were 14.3%, 23.7%, and 17.9%, respectively. However, the 
prevalence for GOLD stages 2–4 remained unchanged between the Mini-
Finland Health Survey and the Health 2000 Survey [3,134].  
One specific weakness in the TB diagnostics is that the radiologists together 
formulated the diagnostic criteria for TB indicative scarring on a chest x-ray, 
but these criteria are no longer available. The scars were not classified more 
specifically. Another major change and limitation lies in the significantly 
improved vitamin D status in the Finnish population between 2000 and 2011 
(vitamin D fortification policy from 2003) [34,100]. In addition, other baseline 
characteristics measured, such as weight and leisure physical activity, may 
have changed during follow-up affecting the results. These effects include 
changes in medical treatments for various diseases, particularly 
cardiovascular disease, and possible minor changes to causes of death and 
their documentation. These limitations are typically associated with 
retrospective health examination surveys.  
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7 CONCLUSIONS 
In conclusion, bronchial obstruction predicts all-cause mortality based on the 
GOLD stage. Obstruction identified in individuals under 50 years old might be 
more detrimental than when diagnosed at an older age. In addition, 
obstruction strongly predicts coronary mortality, but not MI. Morever, 
obstruction and past TB have an additive joint effect on all-cause mortality. 
Finally, a low vitamin D status may be more detrimental in subjects with 
obstruction than in others.  
Thus far, little epidemiological research has focused on obstruction in 
relation to the size of the problem. Hence, further epidemiological studies 
should aim to add knowledge on its causes and consequences. 
On the basis of this doctoral study, no clinical implication could be strictly 
proposed. In general, however, physicians should consider obstruction a 
significant risk factor for premature mortality.  
We suggest the following topics for future studies: 
- Why does obstruction predict coronary death, while the association 
between obstruction and MI remains less consistent?  
- What are the pathophysiological mechanisms behind the association 
between obstruction and cardiovascular diseases? 
- Is there any difference between COPD and obstruction in terms of the 
associations with cardiovascular risks and all-cause and cause-specific 
mortality? 
- Could obstruction be an indicator for cardiovascular mortality risk? 
- What role does obstruction measured in younger subjects play in their 
later morbidity?  
- Do pulmonary infections other than TB serve as risk factors for 
obstruction? 
- What unknown risk factors for COPD exist among never-smokers?  
- What is the effect of a low vitamin D status on the prognosis for 
obstruction? 
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